"Dyskinesia, Drug-Induced" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Descriptor ID |
D004409
|
| MeSH Number(s) |
C10.228.662.262.500 C10.597.350.275 C10.720.312 C23.888.592.350.275 C25.100.750 C25.723.705.200
|
| Concept/Terms |
Dyskinesia, Drug-Induced- Dyskinesia, Drug-Induced
- Drug-Induced Dyskinesia
- Drug-Induced Dyskinesias
- Dyskinesia, Drug Induced
- Dyskinesias, Drug-Induced
Dyskinesia, Medication-Induced- Dyskinesia, Medication-Induced
- Dyskinesia, Medication Induced
- Dyskinesias, Medication-Induced
- Medication-Induced Dyskinesias
- Medication-Induced Dyskinesia
- Medication Induced Dyskinesia
|
Below are MeSH descriptors whose meaning is more general than "Dyskinesia, Drug-Induced".
Below are MeSH descriptors whose meaning is more specific than "Dyskinesia, Drug-Induced".
This graph shows the total number of publications written about "Dyskinesia, Drug-Induced" by people in this website by year, and whether "Dyskinesia, Drug-Induced" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2017 | 6 | 1 | 7 |
| 2018 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dyskinesia, Drug-Induced" by people in Profiles.
-
Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease. Mov Disord. 2021 10; 36(10):2219.
-
Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Neurobiol Aging. 2019 09; 81:177-189.
-
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018 12; 84(6):797-811.
-
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease. Neurosci Lett. 2019 01 18; 690:83-88.
-
Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities. J Neural Transm (Vienna). 2018 08; 125(8):1263-1271.
-
Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord. 2018 07; 33(6):867-876.
-
Impulse control disorders in advanced Parkinson's disease with dyskinesia: The ALTHEA study. Mov Disord. 2017 Nov; 32(11):1557-1565.
-
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias. Neurobiol Dis. 2017 Dec; 108:54-64.
-
Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2018 Mar; 89(3):323-324.
-
Mucuna pruriens in Parkinson disease: A double-blind, randomized, controlled, crossover study. Neurology. 2017 Aug 01; 89(5):432-438.